An inhibitor of oxidative phosphorylation exploits cancer vulnerability

doi:10.1038/s41591-018-0052-4

. 2018 Jul;24(7):1036-1046.

doi: 10.1038/s41591-018-0052-4. Epub 2018 Jun 11.

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R Molina^{1

2}, Yuting Sun^{1

2}, Marina Protopopova^{1

2}, Sonal Gera^{1

2}, Madhavi Bandi^{1

2}, Christopher Bristow^{1

2}, Timothy McAfoos¹, Pietro Morlacchi^{1

3}, Jeffrey Ackroyd⁴, Ahmed-Noor A Agip⁵, Gheath Al-Atrash⁶, John Asara⁷, Jennifer Bardenhagen¹, Caroline C Carrillo⁸, Christopher Carroll¹, Edward Chang^{1

2}, Stefan Ciurea⁶, Jason B Cross¹, Barbara Czako¹, Angela Deem^{1

2}, Naval Daver⁹, John Frederick de Groot⁸, Jian-Wen Dong⁸, Ningping Feng^{1

2}, Guang Gao^{1

2}, Jason Gay^{1

2}, Mary Geck Do¹, Jennifer Greer¹, Virginia Giuliani^{1

2}, Jing Han^{1

2}, Lina Han⁹, Verlene K Henry⁸, Judy Hirst⁵, Sha Huang¹, Yongying Jiang¹, Zhijun Kang¹, Tin Khor^{1

2}, Sergej Konoplev¹⁰, Yu-Hsi Lin⁴, Gang Liu¹, Alessia Lodi¹¹, Timothy Lofton¹, Helen Ma⁹, Mikhila Mahendra^{1

2}, Polina Matre⁹, Robert Mullinax^{1

2}, Michael Peoples^{1

2}, Alessia Petrocchi¹, Jaime Rodriguez-Canale¹², Riccardo Serreli⁵, Thomas Shi^{1

2}, Melinda Smith^{1

2}, Yoko Tabe^{9

13}, Jay Theroff¹, Stefano Tiziani¹¹, Quanyun Xu¹, Qi Zhang⁹, Florian Muller⁴, Ronald A DePinho¹⁴, Carlo Toniatti^{1

2}, Giulio F Draetta^{1

2

15}, Timothy P Heffernan^{1

2}, Marina Konopleva⁹, Philip Jones¹, M Emilia Di Francesco¹, Joseph R Marszalek^{16

17}

Affiliations

¹ Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Agilent Technologies Inc., Lexington, MA, USA.
⁴ Department of Cancer Imaging Systems, University of Texas MD Cancer Center, Houston, TX, USA.
⁵ Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK.
⁶ Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
⁸ Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁰ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹¹ Department of Nutritional Sciences, University of Texas at Austin, Austin, TX, USA.
¹² Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹³ Department of Next Generation Hematology Laboratory Medicine, Department of Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.
¹⁴ Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁵ Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁶ Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrmarszalek@mdanderson.org.
¹⁷ Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrmarszalek@mdanderson.org.

PMID: 29892070
DOI: 10.1038/s41591-018-0052-4

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R Molina et al. Nat Med. 2018 Jul.

. 2018 Jul;24(7):1036-1046.

doi: 10.1038/s41591-018-0052-4. Epub 2018 Jun 11.

Authors

Affiliations

¹ Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Agilent Technologies Inc., Lexington, MA, USA.
⁴ Department of Cancer Imaging Systems, University of Texas MD Cancer Center, Houston, TX, USA.
⁵ Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK.
⁶ Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
⁸ Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁰ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹¹ Department of Nutritional Sciences, University of Texas at Austin, Austin, TX, USA.
¹² Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹³ Department of Next Generation Hematology Laboratory Medicine, Department of Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.
¹⁴ Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁵ Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁶ Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrmarszalek@mdanderson.org.
¹⁷ Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrmarszalek@mdanderson.org.

PMID: 29892070
DOI: 10.1038/s41591-018-0052-4

Abstract

Metabolic reprograming is an emerging hallmark of tumor biology and an actively pursued opportunity in discovery of oncology drugs. Extensive efforts have focused on therapeutic targeting of glycolysis, whereas drugging mitochondrial oxidative phosphorylation (OXPHOS) has remained largely unexplored, partly owing to an incomplete understanding of tumor contexts in which OXPHOS is essential. Here, we report the discovery of IACS-010759, a clinical-grade small-molecule inhibitor of complex I of the mitochondrial electron transport chain. Treatment with IACS-010759 robustly inhibited proliferation and induced apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS, likely owing to a combination of energy depletion and reduced aspartate production that leads to impaired nucleotide biosynthesis. In models of brain cancer and AML, tumor growth was potently inhibited in vivo following IACS-010759 treatment at well-tolerated doses. IACS-010759 is currently being evaluated in phase 1 clinical trials in relapsed/refractory AML and solid tumors.

PubMed Disclaimer

Cited by

Overcoming Barriers in Photodynamic Therapy Harnessing Nanogenerators Strategies.
Zhou Y, Zou P, Chen X, Chen P, Shi M, Lang J, Chen M. Zhou Y, et al. Int J Biol Sci. 2024 Oct 14;20(14):5673-5694. doi: 10.7150/ijbs.100317. eCollection 2024. Int J Biol Sci. 2024. PMID: 39494340 Free PMC article. Review.
The immunometabolic ecosystem in cancer.
Bantug GR, Hess C. Bantug GR, et al. Nat Immunol. 2023 Dec;24(12):2008-2020. doi: 10.1038/s41590-023-01675-y. Epub 2023 Nov 27. Nat Immunol. 2023. PMID: 38012409 Review.
Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer.
Wu Z, Lee YF, Yeo XH, Loo SY, Tam WL. Wu Z, et al. Cancers (Basel). 2021 Mar 15;13(6):1316. doi: 10.3390/cancers13061316. Cancers (Basel). 2021. PMID: 33804114 Free PMC article. Review.
Secretome of Dental Pulp-Derived Stem Cells Reduces Inflammation and Proliferation of Glioblastoma Cells by Deactivating Mapk-Akt Pathway.
Prateeksha P, Howlader MSI, Hansda S, Naidu P, Das M, Abo-Aziza F, Das H. Prateeksha P, et al. Dis Res. 2023 Dec;3(2):74-86. doi: 10.54457/DR.202302006. Epub 2023 Jul 19. Dis Res. 2023. PMID: 38213319 Free PMC article.
Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759.
Pujalte-Martin M, Belaïd A, Bost S, Kahi M, Peraldi P, Rouleau M, Mazure NM, Bost F. Pujalte-Martin M, et al. Mol Oncol. 2024 Jul;18(7):1719-1738. doi: 10.1002/1878-0261.13583. Epub 2024 Jan 12. Mol Oncol. 2024. PMID: 38214418 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Affiliations

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources